Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates [Yahoo! Finance]
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
with generalized myasthenia gravis (MG), an autoimmune disease associated with muscle weakness. A total of 36 heavily pre-treated, highly symptomatic MG patients were randomized equally to receive either Descartes-08 or placebo, administered as six weekly outpatient infusions without preconditioning chemotherapy in this phase IIb double-blind, placebo-controlled, crossover study. Patients receiving placebo were eligible to cross over to Descartes-08 treatment at the conclusion of the trial's blinded follow-up assessment after three months. Descartes-08 is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) directed against the B cell maturation antigen. mRNA CAR-T administration does not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation unlike conventional DNA-based CAR T-cell therapies. The study achieved its primary en
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
- Gout (Chronic Refractory) Market Assessment 2024 Featuring 15 Companies and 20 Key Drugs - Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile DermatomyositisGlobeNewswire
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 10/2/24 - Form EFFECT
- 10/1/24 - Form 424B7
- 9/27/24 - Form SC
- RNAC's page on the SEC website